>북미 눈 통증 시장, 질병 유형별(눈 질환이 있는 눈 통증 및 기본 눈 질환이 없는 눈 통증), 유형(진단 및 치료), 적용(결막염, 각막 찰과상, 안검염, 다래끼, 홍채염, 부비동염, 편두통, 녹내장 및 기타), 투여 경로(국소, 눈 주위, 눈 내, 경구 및 기타), 약물 유형(처방 및 일반 의약품), 인구 유형(성인 및 노인), 최종 사용자(병원, 전문 클리닉, 재택 의료 시설, 안과 센터, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 및 기타), 국가(미국, 캐나다, 멕시코) - 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 북미 안구 통증 시장
북미 눈 통증 시장은 2021년부터 2028년까지의 예측 기간 동안 성장할 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 5.7%의 CAGR로 성장하고 있으며 2028년까지 6억 9,919만 달러에 도달할 것으로 예상한다고 분석했습니다. 비위생적이고 앉아서 보내는 생활 방식의 증가는 북미 눈 통증 시장 성장을 촉진하는 요인으로 작용합니다.
눈의 통증은 눈의 통증이라고도 하며, 일반적으로 가벼운 자극으로 인해 발생하지만 심각한 질환의 증상은 드뭅니다. 대부분의 통증은 약이나 추가 치료 없이 해소되며 자가 면역 체계에 의해 회복됩니다. 그러나 근본적인 원발성 안과 질환 이 있는 눈의 통증 은 시기적절한 치료가 필요합니다. 눈의 통증은 일반적으로 눈의 표면에서 발생하는 눈의 통증과 같이 두 가지 범주로 분류되며 긁힘, 타는 듯한 느낌 또는 가려움증을 유발합니다. 이는 사람의 속눈썹, 이물질, 감염 또는 외상으로 인해 발생합니다. 눈의 통증은 종종 점안액과 국소 스테로이드 또는 NSAID로 치료합니다. 눈의 통증은 결막염, 콘택트 렌즈 자극, 각막 찰과상, 부상, 안검염 및 다래끼와 같은 근본적인 원발성 안과 질환과 함께 발생합니다. 자극 요법과 같은 다른 고급 치료법도 적절하게 진단된 심각한 신경 안구 통증에 사용됩니다.
Increasing unhygienic and sedentary lifestyles, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the North America ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the North America ocular pain market growth. Increasing research and development activities, rising healthcare expenditure and disposable income, and growing geriatric population acts as opportunities for the North America ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework poses a challenge for the North America ocular pain market growth.
North America ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
North America Ocular Pain Market Scope and Market Size
North America ocular pain market is segmented on the basis of the disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the North America ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the North America ocular pain market as ocular pain is the initial symptom of most eye diseases.
- On the basis of type, the North America ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to raising funds for research activities over diagnostic ophthalmology.
- On the basis of application, the North America ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate dominating the market due to less awareness during the initial stages of pain.
- 투여 경로를 기준으로 북미 눈 통증 시장은 국소, 눈 주위, 눈 내, 경구 및 기타로 세분화됩니다. 2021년에는 국소 세그먼트가 시장을 지배할 것으로 예상되며, 눈 관리를 위해 방대한 국소 솔루션과 제품이 구현되고 있습니다.
- 약물 유형에 따라 북미 안구 통증 시장은 처방과 일반 의약품으로 세분화됩니다. 2021년에는 처방 부문이 시장을 지배할 것으로 예상되며, OTC 약물에 대한 정부 규제와 지침이 강화됨에 따라 처방이 의무화되었습니다.
- 인구 유형을 기준으로 북미 안구 통증 시장은 성인과 노인으로 세분화됩니다. 2021년에는 성인 세그먼트가 좌식 생활 방식과 습관이 증가함에 따라 시장을 지배할 것으로 예상됩니다.
- 최종 사용자를 기준으로 북미 안구 통증 시장은 병원, 전문 클리닉, 홈 헬스케어, 안과 센터, 외래 수술 센터 등으로 세분화됩니다. 2021년에는 높은 경제 성장으로 인해 북미 선진국에 병원이 늘어나면서 병원 부문이 시장을 지배할 것으로 예상됩니다.
- 유통 채널을 기준으로 북미 안구 통증 시장은 직접 입찰, 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년에는 직접 입찰 부문이 고품질 제품을 제공하므로 시장을 지배할 것으로 예상됩니다.
북미 안구 통증 시장 국가 수준 분석
북미 안구 통증 시장을 분석하고, 위에 언급된 대로 국가, 질병 유형, 유형, 응용 분야, 투여 경로, 약물 유형, 인구 유형, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
북미 안구 통증 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.
북미 지역의 미국 진단 부문은 안과 질환 사례가 증가함에 따라 2021년에서 2028년의 예측 기간에 가장 높은 성장률을 기록할 것으로 예상됩니다. 캐나다의 진단 부문은 사람들의 비위생적인 습관이 증가함에 따라 북미에서 두 번째로 큰 시장입니다. 멕시코는 이 지역에서 세 번째로 큰 시장이며, 진단 부문은 시장 참여자와 이니셔티브의 수가 증가함에 따라 이 나라에서 우위를 점하고 있습니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
주요 시장 참여자들의 눈 통증 치료에 대한 인식을 높이기 위한 전략적 활동이 확대되면서 북미 눈 통증 시장 의 시장 성장이 촉진되고 있습니다.
북미 안구 통증 시장은 또한 특정 시장에서 모든 국가의 성장에 대한 자세한 시장 분석을 제공합니다. 또한 시장 참여자의 전략과 지리적 입지에 대한 자세한 정보를 제공합니다. 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 북미 안구 통증 시장 점유율 분석
북미 안구 통증 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 범위, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 회사가 북미 안구 통증 시장에 집중하는 것과만 관련이 있습니다.
북미 안구 통증 시장을 다루는 주요 기업으로는 Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.(Merck & Co., Inc.의 자회사), Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd, Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Kala Pharmaceuticals, Novartis AG, Omeros Corporation, Allergan(AbbVie 회사), SiteOne Therapeutics, Inc., OKYO Pharma Limited, Fera Pharmaceuticals, Vyluma, TALLC Inc., IACTA Pharmaceuticals, Inc., Allakos Inc., Aldeyra Therapeutics, Inc., Novaliq GmbH 등이 있으며, 국내 기업도 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사가 많은 계약과 협정을 체결하면서 북미 안구 통증 시장이 급속히 성장하고 있습니다.
예를 들어,
- 2020년 11월, Allakos Inc.는 American College of Gastroenterology(ACG) 2020 연례 과학 회의에 참여했습니다. 이 회사는 참석한 고객에게 호산구성 위장관 질환 및 기타 질환에 대한 제품을 발표했습니다. 이를 통해 시장에서의 입지를 강화했습니다.
- 2020년 10월, Aldeyra Therapeutics, Inc.는 2상을 넘어선 Reproxalap 안과용액(0.25% 및 0.5%)의 임상 데이터를 발표했습니다. 또한 알레르기성 결막염에 대한 적용도 시연했습니다. 이를 통해 집중 시장에서의 입지를 강화했습니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 안구 통증 시장에서 회사의 입지를 강화하고, 이는 조직의 수익 성장에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISEASE TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS
4.4 VOLUME OF PRESCRIPTION
5 PIPELINE ANALYSIS
6 REGIONAL SUMMARY
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 THE MIDDLE EAST AND AFRICA
7 NORTH AMERICA OCULAR PAIN MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
8.1.4 GROWING CASES OF OCULAR MIGRAINE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.3.3 INCREASING GERIATRIC POPULATION
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
9 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA OCULAR PAIN MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 OCULAR PAIN WITH EYE DISEASES
10.2.1 OCULAR PAIN WITH RED EYE
10.2.2 OCULAR PAIN WITHOUT RED EYE
10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
10.3.1 OCULAR MIGRAINE
10.3.2 GIANT CELL ARTERITIS
10.3.3 TRIGEMINAL NEURALGIAS
10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES
10.3.5 CAROTID ARTERY DISSECTION
10.3.6 CAROTIDYNIA
10.3.7 OTHERS
11 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 SENSORY TESTING
11.2.1.1 HAND LIGHT EXAMINATION
11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS
11.2.1.3 SLIT LAMP EXAMINATION
11.2.1.4 FLUORESCEIN EXAMINATION
11.2.2 IMAGING TEST
11.2.2.1 CONFOCAL MICROSCOPY
11.2.2.2 FUNCTIONAL MRI
11.3 TREATMENT
11.3.1 LOCAL TREATMENT
11.3.1.1 TOPICAL STEROID
11.3.1.1.1 LOTEPREDNOL
11.3.1.1.2 DEXAMETHASONE
11.3.1.1.3 PREDNISOLONE
11.3.1.1.4 FLUOROMETHOLONE
11.3.1.1.5 OTHERS
11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)
11.3.1.2.1 BROMFENAC
11.3.1.2.2 KETOROLAC
11.3.1.2.3 NEPAFENAC
11.3.1.2.4 DICLOFENAC
11.3.1.2.5 OTHERS
11.3.1.3 OTHERS
11.3.2 STIMULATION THERAPIES
11.3.2.1 DEEP BRAIN STIMULATION
11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)
11.3.2.4 SCRAMBLER THERAPY
11.3.2.5 OTHERS
11.3.3 OTHERS
12 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 GLAUCOMA
12.3 BLEPHARITIS
12.4 CONJUNCTIVITIS
12.5 CORNEAL ABRASION
12.6 STY
12.7 IRITIS
12.8 SINUSITIS
12.9 MIGRAINES
12.1 OTHERS
13 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 SOLUTION
13.2.2 GELS
13.2.3 OINTMENTS
13.2.4 OTHERS
13.3 INTRAOCULAR
13.3.1 INTRAVITREAL
13.3.2 INTRACAMERAL
13.4 PERIOCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 SUBTENON
13.4.3 PERIBULBAR
13.4.4 RETROBULBAR
13.5 ORAL
13.5.1 TABLETS
13.5.2 CAPSULE
13.5.3 OTHERS
13.6 OTHERS
14 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 OVER THE COUNTER
15 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 ADULTS
15.3 GERIATRIC
16 NORTH AMERICA OCULAR PAIN MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OPHTHALMOLOGY CENTERS
16.6 AMBULATORY SURGICAL CENTERS
16.7 OTHERS
17 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 NORTH AMERICA OCULAR PAIN MARKET, BY GEOGRAPHY
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA OCULAR PAIN MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 BAUSCH & LOMB INCORPORATED
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 NOVARTIS AG
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 OMEROS CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 AKORN OPERATING COMPANY LLC
21.5.1 COMPANY SNAPSHOT
21.5.2 COMPANY SHARE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 AERIE PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALDEYRA THERAPEUTICS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 PRODUCT PORTFOLIO
21.7.3 RECENT DEVELOPMENTS
21.8 ALLAKOS INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 ALLERGAN (AN ABBVIE COMPANY)
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 EYEPOINT PHARMACEUTICALS, INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 FERA PHARMACEUTICALS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 FORMOSAPHARMA PHARMACEUTICAL INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENT
21.13 IACTA PHARMACEUTICALS, INC.
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 KALA PHARMACEUTICALS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 NOVALIQ GMBH
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 OCULAR THERAPEUTIX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 OKYO PHARMA LIMITED
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PFIZER, INC.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 PHARMALEADS SA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 SITEONE THERAPEUTICS, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENT
21.23 SYLENTIS
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENT
21.24 TALLC INC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENT
21.25 TARSIER PHARMA LTD.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENT
21.26 VYLUMA
21.26.1 COMPANY SNAPSHOT
21.26.2 PRODUCT PORTFOLIO
21.26.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
표 목록
TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS
TABLE 2 VOLUME OF PRESCRIPTION (%)
TABLE 3 NORTH AMERICA OCULAR PAIN MARKET, PIPELINE ANALYSIS
TABLE 4 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 77 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 80 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 102 U.S. OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 124 CANADA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 127 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 139 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OCULAR PAIN MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE NORTH AMERICA OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OCULAR PAIN MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA OCULAR PAIN MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)
FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)
FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)
FIGURE 19 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2020
FIGURE 20 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2020
FIGURE 28 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2020
FIGURE 36 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2020
FIGURE 40 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2020
FIGURE 44 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 48 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 49 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 50 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA OCULAR PAIN MARKET: SNAPSHOT (2020)
FIGURE 52 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020)
FIGURE 53 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
